A phase I pharmacokinetics trial comparing PF‐05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis

AIMS: Pharmacokinetic (PK) similarity was assessed among PF‐05280586 (a proposed biosimilar) vs. rituximab sourced from the European Union (rituximab‐EU) and the United States (rituximab‐US). Pharmacodynamics (PD), overall safety and immunogenicity were also evaluated. METHODS: Patients with active...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Stanley, Emery, Paul, Greenwald, Maria, Yin, Donghua, Becker, Jean‐Claude, Melia, Lisa Ann, Li, Ruifeng, Gumbiner, Barry, Thomas, Dolca, Spencer‐Green, George, Meng, Xu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Pharmacokinetic Dynamic Relationships
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917800/
https://www.ncbi.nlm.nih.gov/pubmed/26909489
http://dx.doi.org/10.1111/bcp.12916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917800/
https://www.ncbi.nlm.nih.gov/pubmed/26909489
http://dx.doi.org/10.1111/bcp.12916

Ejemplares similares